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Abstract We have characterised the mechanisms involved in the
antiproliferative effect of NO in human airway smooth muscle
cells (HASMC). S-Nitroso-N-acetyl penicillamine, a nitric oxide
donor, inhibited proliferation in both G1 and S phases of the cell
cycle. Additionally, experiments with 8-bromo-cGMP, haemo-
globin, a NO scavenger and zaprinast, a cGMP-specific
phosphodiesterase inhibitor, showed that both effects were NO-
mediated. The G1 phase inhibition was cGMP-dependent
whereas the S phase inhibition was due to a cGMP-independent
inhibition of ribonucleotide reductase. These results demonstrate
that NO inhibits HASMC proliferation by cGMP-dependent
and -independent mechanisms acting at distinct points in the cell
cycle. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In chronic asthma there is an increase in airway smooth
muscle (ASM) mass, which appears to be due to hyperplasia
and hypertrophy. This contributes to increased thickness of
the airway wall and the resulting poorly reversible air£ow
obstruction, which characterises chronic asthma [1]. It is not
clear whether the increase in ASM mass occurs as a result of
overproduction of growth factors or loss of an inhibitory
in£uence, or both. Recent studies have identi¢ed several
growth factors for ASM in a number of species [2,3] but little
is known about the mechanisms and pathways inhibiting
ASM proliferation.
The synthesis of cGMP is catalysed by guanylyl cyclases
(GC), which exist in two forms: a soluble (cytosolic) form,
activated by nitric oxide (NO) [4], and a particulate (mem-
brane-bound) form, activated by natriuretic peptides [5]. We
have previously shown that both GC forms were abundant
suggesting that they are functionally important [6]. NO is
produced by the airway epithelium where it has a paracrine
bronchoprotective role [7,8] and by non-adrenergic non-chol-
inergic nerves where it acts as an inhibitory neurotransmitter
causing cGMP-mediated ASM relaxation [9,10]. NO has both
cGMP-dependent and -independent e¡ects on proliferation in
other biological systems [11^14] and we have recently shown
that continuous exposure to S-nitroso-N-acetyl penicillamine
(SNAP) or 8-bromo-cGMP inhibits mitogen-induced prolifer-
ation in human airway smooth muscle cells (HASMC) [15].
HASMC had been shown to express type I nitric oxide syn-
thase which results in inhibition of DNA synthesis and cell
proliferation [16].
Regulation of cell cycle progression through the G1 phase
by extracellular factors is possible until the restriction point
which occurs late in G1 phase. This restriction point demar-
cates the commitment to subsequent DNA replication in the
S phase and obligatory cell division in the M phase. Cells that
have traversed the restriction point no longer require protein
synthesis and are not dependent on extracellular growth fac-
tors. There is some evidence to suggest that the contractile
properties of ASM are altered in asthma with promotion of
the proliferative phenotype [17]. Endogenous antiproliferative
substances such as transforming growth factor-L, heparin and
prostaglandin E2 [18,19] inhibit ASM cell progression at var-
ious points prior to the restriction point. This study character-
ises the intracellular mechanisms and cell cycle speci¢city of
NO inhibition of HASMC proliferation. We used thymidine
incorporation to measure proliferation in these studies but
have previously shown that changes in thymidine incorpora-
tion are representative of changes in other proliferative indices
such as cell counts or MTT incorporation after SNAP treat-
ment [15].
2. Materials and methods
2.1. Materials
[3H]Thymidine was obtained from Amersham Life Science (Little
Chalfont, UK), foetal bovine serum (FBS) was purchased from JRH
Biosciences (Sera-Lab, Sussex, UK). All other chemicals were pur-
chased from Sigma-Aldrich (Poole, UK). Plasticware was purchased
from Costar (Cambridge, MA, USA).
2.2. Cell culture
Primary cultures of HASMC were prepared from explants of ASM
from two donors according to methods previously described [6,20,21].
We have shown, using morphological and immunohistochemical
staining, that this method produces a relatively pure (s 95%) popu-
lation of ASM cells.
2.3. [3H]Thymidine incorporation
Frozen aliquots of cells were thawed before use and plated at a
density of 2U104 cells/ml in 96-well culture plates containing Dulbec-
co’s modi¢ed Eagle’s medium supplemented with 10% FBS, antibiot-
ics and 4U1033 M glutamine. At con£uence, cells were growth-ar-
rested by serum deprivation for 24 h. Experimental agents were added
either at the time of the addition of FBS for 24 h (G0/G1 e¡ect) or 24 h
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later when cells re-entered the S phase for 1 h. 4 WCi/ml of
[3H]thymidine was added 24 h after addition of FBS (10 min after
the delayed addition of drugs) for one additional hour. DNA was
isolated using a cell harvester (Automash 2000, Dynatec, West Sussex,
UK), adsorbed onto ¢breglass ¢lters, treated with 200 Wl 0.01 M
potassium hydroxide and immersed in 4 ml scintillation £uid (Ready
protein, Beckman, Fullerton, CA, USA). Radioactivity was quanti¢ed
using a scintillation counter (Minaxi 4000, Packard, CT, USA) with a
counting e⁄ciency of 40%.
2.4. Analyses
Results are shown as means þ S.E.M. [3H]Thymidine incorporation
data are expressed as dpm/well (or as % inhibition of stimulated con-
trols to allow comparison between experimental protocols). The sig-
ni¢cance of drug e¡ect was assessed by one-way analysis of variance
followed by Student’s t-test using the SPSS software program (SPSS,
Chicago, IL, USA). A P value 6 0.05 was regarded as signi¢cant.
3. Results
3.1. Cell cycle synchronisation
Re-addition of serum-containing medium resulted in entry
of cells into the S phase after 18 h, as determined by thymi-
dine incorporation into DNA (Fig. 1). Serial FBS-induced
thymidine incorporations after re-stimulation were (fold in-
crease over unstimulated controls) : 0.7 þ 0.1 at 6 h,
1.2 þ 0.06 at 9 h, 1.0 þ 0.2 at 12 h, 1.4 þ 0.3 at 15 h, 2.1 þ 0.1
at 18 h and 26 þ 1 at 24 h (n = 6 for all, P = 0.27, 0.15, 0.97,
0.16, 6 0.001 and 6 0.001 respectively).
According to these results, we consequently chose to mea-
sure thymidine incorporation in all experiments 24 h after
addition of serum, and evaluated S phase e¡ects of drugs
during a 1 h window from 24 to 25 h after addition of serum.
3.2. Cell cycle studies
To determine the point of action of NO and cGMP in the
cell cycle progression from G0 through G1 into the S phase, a
delayed addition approach was used. At the indicated times
(Fig. 2) after serum re-stimulation of growth-arrested cells,
1034 M SNAP or 1033 M 8-bromo-cGMP were added.
When cells entered the S phase, 24 h after serum re-addition,
DNA synthesis was measured for 1 h by thymidine incorpo-
ration. SNAP inhibited FBS-induced thymidine incorporation
when it was added in the G0/G1 or the S phases. 1034 M
SNAP inhibited FBS-induced mitogenesis by 61 þ 3.8% at
time 0, 68 þ 3.1% at 6 h, 60 þ 3.4% at 12 h and 68 þ 5.0% at
24 h (n = 6, P6 0.001 for all). In contrast, 8-bromo-cGMP
inhibited FBS-induced thymidine incorporation only when
added during the G0/G1 phase of the cell cycle. 1033 M
8-bromo-cGMP inhibited FBS-induced mitogenesis by
39 þ 5.3% at time 0, 49 þ 4.4% at 6 h and 46 þ 4.2% at 12 h
(n = 6, P6 0.001 for all), while it was without e¡ect when
added 24 h after serum addition (n = 6, P = 0.43).
3.2.1. The e¡ect of haemoglobin on the antimitogenic e¡ect
of SNAP. To determine if the inhibitory e¡ect of SNAP was
related to NO donation we studied the e¡ect of haemoglobin
(Hb), an NO scavenger, on the antimitogenic e¡ect of SNAP.
Cells were pretreated with 1035 M Hb for 1 h before the
addition of 1034 M SNAP. Hb alone had an inhibitory e¡ect
on basal and mitogen-stimulated thymidine incorporation
when added in the G0/G1 phase which was reported previ-
ously in these cells and other cell types [15]. The antimitogenic
e¡ect of SNAP in both G0/G1 and S phases was blocked by
Hb pretreatment (Fig. 3).
3.2.2. The e¡ect of methylene blue on the antimitogenic
e¡ect of SNAP. To test whether cGMP was involved in
the antimitogenic e¡ects of SNAP we studied the e¡ect of
methylene blue (MB), an inhibitor of soluble GC. Cells were
pretreated with 2U1036 M MB for 1 h before the addition of
Fig. 1. Stimulation of DNA synthesis in HASMC by FBS. Growth-
arrested cells were stimulated with 10% FBS for 6^24 h as de-
scribed. Data represent the mean þ S.E.M., n = 6. Signi¢cantly di¡er-
ent from serum-free control: ***P6 0.001.
Fig. 2. Inhibition of FBS-induced DNA synthesis by SNAP and
8-bromo-cGMP. Growth-arrested cells were stimulated by 10% FBS
for 24 h. 1034 M SNAP and 1033 M 8-bromo-cGMP were added
at di¡erent time points after addition of FBS. Data represent the
mean þ S.E.M., n = 6.
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1034 M SNAP. MB alone had no signi¢cant e¡ect on basal
and mitogen-stimulated thymidine incorporation. The antimi-
togenic e¡ect of SNAP in both G0/G1 and S phases was
blocked by MB pretreatment (Fig. 4).
3.2.3. E¡ects of zaprinast on the antimitogenic e¡ect of
SNAP. To further test whether cGMP was involved in the
antimitogenic e¡ects of SNAP we studied the e¡ect of zapri-
nast, a cGMP-speci¢c phosphodiesterase (PDE) inhibitor [22].
Fig. 3. E¡ect of Hb on the antimitogenic e¡ects of SNAP added either during the G0/G1 phase (A) or in the S phase (B). Cells were pretreated
with 1035 M Hb for 1 h before the addition of 1034 M SNAP. Data represent the mean þ S.E.M., n = 6.
Fig. 4. E¡ect of MB on the antimitogenic e¡ects of SNAP added either during the G0/G1 phase (A) or in the S phase (B). Cells were pre-
treated with 2U1036 M MB for 1 h before the addition of 1034 M SNAP. Data represent the mean þ S.E.M., n = 6.
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Zaprinast alone did not alter basal or FBS-induced prolifer-
ation, however, the antimitogenic e¡ect of SNAP, in G0/G1
but not S phase, was enhanced in the presence of zaprinast
(Fig. 5).
3.2.4. The e¡ect of deoxynucleosides on the antimitogenic
e¡ect of SNAP. To probe the mechanisms involved in the
antimitogenic e¡ects of SNAP in the S phase, we studied the
e¡ect of deoxynucleosides, to bypass ribonucleotide reductase.
Fig. 5. E¡ect of zaprinast on the antimitogenic e¡ects of SNAP added either during the G0/G1 phase (A) or in the S phase (B). Cells were pre-
treated with 1036 M zaprinast for 1 h before the addition of 1034 M SNAP. Data represent the mean þ S.E.M., n = 6. Signi¢cantly di¡erent
from SNAP alone: **P6 0.01.
Fig. 6. E¡ect of deoxynucleosides on the antimitogenic e¡ects of SNAP added either during the G0/G1 phase (A) or in the S phase (B). Cells
were pretreated with 1034 M deoxynucleosides for 1 h before the addition of 1034 M SNAP. Data represent the mean þ S.E.M., n = 6. Signi¢-
cantly di¡erent from SNAP alone: ***P6 0.001.
FEBS 25281 28-9-01
A.M. Hamad, A.J. Knox/FEBS Letters 506 (2001) 91^9694
Cells were pretreated with 1034 M deoxynucleosides for 1 h
before the addition of 1034 M SNAP. The antimitogenic e¡ect
of SNAP in the S phase, but not G0/G1 phase, was partially
reversed by deoxynucleoside pretreatment (Fig. 6).
3.3. Assessment of cell viability
None of the chemicals or vehicles used caused inhibition
below the mean values for unstimulated cells when prolifera-
tion was assessed by thymidine incorporation, MTT assay or
cell counting, nor was there evidence of cytotoxicity when
measured by trypan blue exclusion.
4. Discussion
The major ¢ndings in this study are that NO inhibits
HASMC proliferation by distinct mechanisms acting at di¡er-
ent points in the cell cycle. cGMP-dependent e¡ects were lo-
calised to late in the G1 phase while NO inhibited DNA syn-
thesis in the S phase via a cGMP-independent mechanism.
This is the ¢rst report to characterise an endogenous sub-
stance inhibiting proliferation of ASM cells after the restric-
tion point of cell cycle control in the late G1 phase at which
cell commit themselves to DNA synthesis in the S phase and
subsequent cell division.
We have shown previously that SNAP elevates intracellular
cGMP in cultured HASMC within minutes [6] and the anti-
mitogenic e¡ect of exogenous 8-bromo-cGMP suggests in-
volvement of the cGMP pathway in the antiproliferative ef-
fects of NO in HASMC [15]. Our cell cycle approach identi¢es
the point of action of the NO^cGMP mechanism and delin-
eates antiproliferative actions of NO which are independent of
cGMP. Our ¢nding that cGMP and SNAP act late in the G1
phase supports the concept that NO-induced cGMP acts via
cross-activation of cAMP-dependent protein kinase [23], be-
cause inhibition of HASMC proliferation by cAMP has been
localised to the late G1 phase of the cell cycle [24].
The antiproliferative e¡ect of SNAP in our study was likely
to be NO-mediated as Hb, an NO scavenger which acts in a
competitive manner [25], abolished the antimitogenic e¡ect of
SNAP. This is consistent with previous studies in other cell
systems [26^28]. Zaprinast, a cGMP-speci¢c PDE inhibitor,
given at a concentration selective for cGMP-speci¢c PDE
[22], potentiated the antimitogenic e¡ect of SNAP in the
G0/G1 phase but not in the S phase of the cell cycle suggesting
cGMP-dependent and -independent mechanisms respectively.
The strongest evidence that the S phase inhibitory e¡ects of
SNAP are cGMP-independent is the loss of the inhibitory
e¡ect of exogenous 8-bromo-cGMP in the S phase and the
preservation of the inhibition by SNAP when added in the
S phase. These results contrast with the e¡ect of MB, an inhib-
itor of soluble GC, which blocked the inhibition by SNAP in
the G0/G1 and S phases. This discrepancy could be explained
by the fact that MB can inactivate NO by generating super-
oxide radicals. In view of this limitation of MB, we tried a
more selective inhibitor of soluble GC, 1H-[1,2,3]oxadiazolo-
[4,3-a]quinoxalin-1-one, however it had a toxic e¡ect over the
time course of our experiments and could not be used. Exog-
enous deoxynucleosides reversed the antiproliferative e¡ect of
SNAP in the S phase, but not the G0/G1 phase of the cell
cycle suggesting that ribonucleotide reductase inhibition is in-
volved. However, the reversal by deoxynucleosides was partial
indicating that other unde¢ned mechanisms besides ribonu-
cleotide reductase may be responsible for inhibition of DNA
synthesis by NO. These results are consistent with previous
data in vascular smooth muscle cells [11].
The ability of NO to inhibit the growth of HASMC in cells
with altered G1 control mechanisms may be signi¢cant to
both the pathogenesis and the treatment of asthma. The im-
portance of the restriction point as a cell cycle checkpoint was
made evident by the ¢nding that cancerous cells have dimin-
ished sensitivity at this point. Moreover, in cardiovascular
diseases a number of vascular smooth muscle cell phenotypes
have been found with decreased sensitivity to endogenous in-
hibitors that can act in the G1 phase, e.g. transforming growth
factor-L1. We speculate that the development of ASM pheno-
types resistant to endogenous growth inhibitors that act in the
late G1 phase, coupled with decreased endogenous NO pro-
duction due to epithelial shedding in asthma, which can in-
hibit the proliferation of ASM cells beyond the restriction
point, may contribute to the increased ASM mass in asthma.
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